Company intelligence / Profile preview

Kadimastem

Ownership: Private
Employees: ~12
Development stage: Other

Overview

Kadimastem has demonstrated safety and initial efficacy in a Phase 1/2a clinical trial with its lead product AstroRx for ALS. Its IsletRx program targeting diabetes has completed a pre-Investigational New Drug (pre‑IND) meeting with the FDA and aims to enter clinical trials soon. The company leverages pluripotent stem cell technology to generate therapeutic-grade astrocytes and pancreatic cells[1][2][3].

Therapeutic areas: EndocrinologyNeurology
Modalities: Cell therapy (derived from human embryonic stem cells)Pluripotent stem cell-derived therapies
Industry: Biotech

Drug pipeline

2 assets

AstroRx

1 more asset in the full pipeline.

Partnerships

Recent partnerships include NLS Pharmaceutics on equity financing and multi-target approaches to diabetes; iTolerance on advancing the IsletRx program toward IND submission[1].

Beyond the preview

Go deeper on Kadimastem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kadimastem.